| Catalog No. | HB927026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG2-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | PDGFR2, Platelet-derived growth factor receptor alpha, RHEPDGFRA, Alpha platelet-derived growth factor receptor, PDGFR-2, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, PDGF-R-alpha, Alpha-type platelet-derived growth factor receptor, CD140a antigen, CD140 antigen-like family member A, PDGFRA, PDGFR-alpha, CD140a |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P16234 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -165°C. |
|---|
| Alternate Names | MEDI-575,CAS:1243266-04-7 |
|---|
| Background | Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
